Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent in Japan for its ...

Augustine Therapeutics NV has synthesized new heteroaryl-amine compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be useful for the treatment of inflammation, autoimmune ...

The claims also include combination therapies comprising use of the hedgehog pathway inhibitors along with an HDAC inhibitors enhancing anti-cancer efficacy. “Issuance of the new patent for our ...

Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China Jiangsu Key Laboratory of Drug Design and ...

A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

With the publication of this study, guselkumab is now the third IL-23 inhibitor to meet its primary efficacy endpoint in this population, joining the already approved mirikizumab and risankizumab. 3,4 ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

School of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia ...

Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful ...